PORTLAND, Oregon, September 22, 2015 /PRNewswire/ --
According to a new report by Allied Market Research, titled, "Global Anti-inflammatory Therapeutics Market - Size, Share, Trend, Company Profiles, Demand, Insights, Analysis, Opportunities, Segmentation, and Forecast, 2014-2020", the global anti-inflammatory therapeutics market is expected to grow at a CAGR of 5.9% from 2015 to 2020. The anti-inflammatory biologics segment held 3/5th of overall market in 2014. The Asia Pacific market would exhibit the highest CAGR of 8.5% during the forecast period.
(Logo: http://photos.prnewswire.com/prnh/20140911/647229)
To view the report, visit the website at https://www.alliedmarketresearch.com/anti-inflammatory-therapeutics-market
Inflammation is the mechanism of innate immunity, which eliminates the cause of injury. Sometimes, the body's defense system inappropriately triggers inflammation against its own cells, resulting in inflammatory autoimmune diseases. Reducing inflammation is one of the primary therapeutic strategies in acute as well as chronic diseases such as arthritis, psoriasis, and asthma. The rising incidences of autoimmune and respiratory conditions, extensive drug development pipeline, and increasing popularity of anti-inflammatory drugs with lesser side effects are the key factors driving the growth of the global anti-inflammatory therapeutics market. In addition, growing awareness about anti-inflammatory therapeutics and government initiatives, in the Asia pacific and LAMEA would further boost the market growth. However adverse effects associated with long term consumption of drugs namely NSAIDs and Corticosteroids would limit the market growth to a certain extent.
The anti-inflammatory biologics hold the largest market share in 2014 and would also exhibit highest growth rate over the forecast period. This is due to the emergence of targeted anti-inflammatory biologics and biosimilars with lesser side effects. Market share of corticosteroids is projected to decrease by 2020, primarily due to withdrawal syndromes. Among indication market, arthritis would continue to lead through 2020 due to high incidence rate and preference of anti-inflammatory biologics for the treatment of arthritis.
Key findings of the study:
In developed economies, such as North America and Europe, branded drugs are preferred over generics whereas there has been a reverse trend in developing economies. This is evident from the fact that about 50% of the anti-inflammatory biologics market has its presence in the North America, whereas, Asia Pacific and LAMEA collectively accounted for 35% share in NSAIDs market as compared to about just 25% share in branded biologics market in 2014.
Companies are adopting drug pipeline development and product launch as key strategies to overcome patent expiries of existing drugs and gain additional market share. Key companies profiled in the report are Pfizer Inc., Abbvie Inc., Johnson & Johnson, GlaxoSmithKline, Merck & CO., Inc. Novartis, F. Hoffman La Roche AG, Eli Lily and Company, AstraZeneca PLC .and Amgen.
Similar market studies by Allied Market Research -
World Asthma and COPD Drug Market - The growth of the Asthma and COPD drugs market is driven by the factors such as raised level of pollution and increasing aging population. Advanced therapies of medical cure and rising disposable income are also contributing to the growth of the market.
To view the asthma and COPD drug Market report, visit the website at https://www.alliedmarketresearch.com/asthma-COPD-drug-market
World Stem Cell Umbilical Cord Blood (UCB) Market - Cord blood stem cell is the only type of stem cell that is stored in controlled condition due to its lower volume higher cell count feature. Storage service market is expected grow at 33.4% CAGR from 2013-2020.
To view the stem cell umbilical cord blood (UCB) market report, visit the website at https://www.alliedmarketresearch.com/stem-cell-umbilical-cord-blood-UCB-market
World Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market - The global CRPC market is expected to reach $9.5 billion by 2020, at a CAGR of 9.1% during the forecast period (2015-2020). Promising drug pipeline, evolving treatment patterns, emerging untapped non-metastatic CRPC space and augmented patient awareness are the factors that are expected to boost the market growth.
To view the castration-resistant prostate cancer (CRPC)/HRPCA therapeutics Market report, visit the website at https://www.alliedmarketresearch.com/castration-resistant-prostate-cancer-therapeutics-market
About Us:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions". AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
Deep Joshi
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Direct: +1(503)505-6949
Toll Free: +1-800-792-5285 (U.S. & Canada)
Fax: +1(855)550-5975
E-mail: sales@alliedmarketresearch.com
Share this article